rs116591906 (SCAND3): No Direct Study Associations
Key takeaways
- rs116591906 is located in the SCAND3 gene, but the provided studies do not report a direct association for this variant.
- A lipid genome-wide study covering 970 plasma lipid species in 6,096 participants from the Rhineland Study did not identify this variant as a significant locus.
- A lung cancer genome-wide meta-analysis combining more than 78,000 cases and 251,000 controls did not report this variant among its findings.
- No lifestyle considerations are on file for this variant based on the current evidence.
Key takeaways
- rs116591906 is located in the SCAND3 (SCAN domain-containing protein 3) gene, but the provided studies do not report a direct association for this variant.
- A genome-wide association study covering 970 plasma complex lipid species in 6,096 participants from the Rhineland Study did not identify this variant as a significant locus.
- A lung cancer genome-wide meta-analysis combining more than 78,000 cases and 251,000 controls did not report this variant among its findings.
- No lifestyle considerations are on file for this variant based on the current evidence.
What the research says
Two population-based genome-wide association studies form the evidence base for this entry. The first analyzed 970 plasma complex lipid species in 6,096 participants from the Rhineland Study, with validation in FinnGen (n = 7,266) and EPIC-Potsdam (n = 1,188), identifying 217 associated genomic loci, of which 136 were novel -- including FDFT1 (a gene involved in cholesterol biosynthesis) -- but reporting no association at this variant or in the SCAND3 gene. The second combined a family-history proxy genome-wide analysis of lung cancer (48,843 proxy cases, 195,387 controls) with an existing lung cancer genome-wide study (29,266 cases, 56,450 controls) and identified 8 novel susceptibility loci in genes including CHEK1 (a DNA repair gene) and CYP1A1 (a metabolic gene), with no reported finding for the variant.
Reported associations
- No direct associations for rs116591906 were reported in the two provided studies.
Evidence quality
The provided evidence base consists of two large genome-wide association studies, neither of which reports this variant as a significant locus. The lipid genome-wide study used a discovery sample of 6,096 participants and validated findings in up to 8,454 additional individuals across two independent cohorts. The lung cancer meta-analysis included 78,109 cases and 251,837 controls, with genome-wide significance defined at the standard threshold of p less than 5 x 10-8. Both are well-powered studies for their respective traits. The absence of this variant from reported findings reflects the scope of these two specific studies and does not constitute a definitive determination of its biological role.
Lifestyle considerations
No lifestyle considerations on file for this variant.
Frequently asked questions
What is rs116591906?
rs116591906 is a single-nucleotide polymorphism, a one-letter change in the DNA sequence, located in the SCAND3 gene. The studies provided for this entry do not report a direct association for this variant with any trait.
What does the SCAND3 gene do?
SCAND3 stands for SCAN domain-containing protein 3. The provided evidence base does not include studies that characterize this gene's function or the biological effects of the rs116591906 variant.
Is rs116591906 linked to lipid levels or lung cancer?
Neither of the two provided studies -- one examining 970 plasma lipid species and one examining lung cancer susceptibility -- reports a direct association for rs116591906.
How strong is the evidence for rs116591906?
The provided evidence base does not include genome-wide significant findings for rs116591906. Its associations, if any exist, are not documented in the studies examined here.